{"id":"NCT05550337","sponsor":"Teva Pharmaceuticals USA","briefTitle":"Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris","officialTitle":"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, PLACEBO CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC. TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., USA), IN THE TREATMENT OF ACNE VULGARIS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-09-19","primaryCompletion":"2023-05-09","completion":"2023-05-09","firstPosted":"2022-09-22","resultsPosted":"2024-09-26","lastUpdate":"2024-09-26"},"enrollment":807,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"OTHER"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Trifarotene 0.005 % Topical Cream","otherNames":[]},{"type":"DRUG","name":"AKLIEF®","otherNames":["Trifarotene 0.005 % Topical Cream"]},{"type":"DRUG","name":"Placebo","otherNames":["Vehicle of Test Product"]}],"arms":[{"label":"Test: Trifarotene Cream, 0.005%","type":"EXPERIMENTAL"},{"label":"AKLIEF®","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle Product","type":"PLACEBO_COMPARATOR"}],"summary":"To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.","primaryOutcome":{"measure":"Primary Change in Inflammatory Lesion Counts","timeFrame":"Baseline and 12 Weeks","effectByArm":[{"arm":"Test: Trifarotene Cream, 0.005%","deltaMin":-72.86,"sd":33.364},{"arm":"AKLIEF®","deltaMin":-78.83,"sd":23.547},{"arm":"Vehicle Product","deltaMin":-34.12,"sd":38.332}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":269},"commonTop":["Headache","Nasopharyngitis","Application site dryness","Upper respiratory tract infection","Dysmenorrhoea"]}}